Jumpgate: Jumpgate Q3 2024: First profitable quarter (Redeye)

WntResearch: WntResearch: Q3 cash position aligned with our expectations (Redeye)

Lipigon Pharmaceuticals: Lipigon Pharmaceuticals: Ask questions to Redeye's analyst (Redeye)

Umida Group: Aktieanalys på Umida Group - Stärkta marginaler i spåren av Jolucas framgångsrika lansering (Analyst Group)

Scandinavian Medical Solutions: Scandinavian Medical Solutions (One-pager): The foundation is now built for the next growth phase (HC Andersen Capital via Inderes)

Northbaze Group: Northbaze Group Q3 2024: 73% Y/Y growth with solid profitability (Redeye)

Canatu: Canatu Intiation of Coverage: Attractive growth story also reflected in valuation (Inderes)

OncoZenge: OncoZenge - Ett betydande bakslag (Impala Nordic)

Gotlandsbolaget: Gotlandsbolaget: Solid Q3, but new route creates uncertainty - SEB (SEB Research)

Lipigon Pharmaceuticals: Lipigon Q3 2024: First Patient Recruited (Redeye)

Dignitana: Dignitana: Intervju med vd Fredrik Jonsson (Redeye)

Waystream Group: Waystream: Intervju med vd Fredrik Lundberg (Redeye)

SP Group: SP Group (One-pager): Accelleration continues as own-brands reach record level (HC Andersen Capital via Inderes)

First Venture Sweden: Analyst Group kommenterar First Ventures Q3-rapport (Analyst Group)

Eolus Vind: Eolus: Interview - A soft quarter but prospects for the future are bright (Carnegie)

Scandinavian Enviro Systems: Enviro Q3 2024: Black figures driven by milestone payments (Redeye)

Maha Energy: Maha Energy: Waiting for Venezuela to clear (Penser Access)

Embracer Group: Embracer Group: Here is what the investors are asking (Redeye)

Nekkar: Nekkar: Here is what the investors are asking (Redeye)

Coegin Pharma: Coegin Pharma: Here is what the investors are asking (Redeye)

Alimak Group: Alimak Group: Fortsatt fokus på lönsam tillväxt (Inderes)

OncoZenge: OncoZenge: Pharmanovia discontinues partnership (Redeye)

Viva Wine: Research update Viva Wine Group, Q3 2024: Solid Nordics operations drive margin recovery (Carlsquare)

Kentima Holding: ANALYS Kentima: Imponerande resultat trots en svag marknad (Analysguiden)

Jumpgate: Jumpgate Q3 2024: In line with expectations (Redeye)

Waystream Group: Waystream Q4’24: Continued sales volatility (Redeye)

Beyond Frames Entertainment: Beyond Frames Q3 2024: “Grim” soon in Open Beta (Redeye)

Flexion Mobile: Flexion Mobile: Ask questions to Redeye's analyst (Redeye)

Kinda Brave: Analyst Group kommenterar Kinda Braves förlagsavtal med Aurora Punks avseende spelet Go Fight Fantastic (Analyst Group)

Dovre Group: NYAB expands geographically by acquiring businesses from Dovre Group (Inderes)

Gotlandsbolaget: Gotlandsbolaget Q3: Solid result - SEB (SEB Research)

Dignitana: Dignitana Q3’24: Sales in line and better cost control (Redeye)

Waystream Group: Waystream Groups rörelseresultat under förväntningarna (Pinpoint Estimates)

Curasight: Curasight: Q3 report and exercise period in warrant TO2 starts (HC Andersen Capital via Inderes)

Eolus Vind: Eolus Vind - Look past the small Q3 (ABG Sundal Collier)

Beyond Frames Entertainment: Beyond Frames Entertainments resultat under förväntningarna (Pinpoint Estimates)

Zinzino: Analysuppdatering Zinzino, kv3 2024: Tillväxtutsikter övertrumfar marginalavvikelse (Carlsquare)

Zinzino: Research update Zinzino, Q3 2024: Growth outlook trumps margin slip (Carlsquare)

Anora Group: Anora: Viva Wine, the main competitor in wines, continued its good development in Q3 (Inderes)

Xbrane Biopharma: Xbrane Biopharma: Interview with CEO Martin Åmark (Redeye)